1. Home
  2. MIRM vs GFF Comparison

MIRM vs GFF Comparison

Compare MIRM & GFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$64.32

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo Griffon Corporation

GFF

Griffon Corporation

HOLD

Current Price

$76.72

Market Cap

3.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
GFF
Founded
2018
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.6B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
GFF
Price
$64.32
$76.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$87.55
$95.75
AVG Volume (30 Days)
616.7K
360.4K
Earning Date
11-04-2025
11-19-2025
Dividend Yield
N/A
1.14%
EPS Growth
N/A
N/A
EPS
N/A
1.09
Revenue
$471,794,000.00
$2,519,926,000.00
Revenue This Year
$53.78
$1.35
Revenue Next Year
$19.91
$3.17
P/E Ratio
N/A
$70.64
Revenue Growth
53.66
N/A
52 Week Low
$36.88
$63.92
52 Week High
$78.55
$84.24

Technical Indicators

Market Signals
Indicator
MIRM
GFF
Relative Strength Index (RSI) 35.49 61.17
Support Level $63.66 $72.67
Resistance Level $66.77 $74.27
Average True Range (ATR) 2.99 1.99
MACD -0.69 0.54
Stochastic Oscillator 9.63 85.92

Price Performance

Historical Comparison
MIRM
GFF

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About GFF Griffon Corporation

Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.

Share on Social Networks: